TCGA-E2-A1L7-01A-11R-A144-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 61
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.620
- G2M_CHECKPOINT+0.550
- ALLOGRAFT_REJECTION+0.380
- MYC_TARGETS_V1+0.350
- MITOTIC_SPINDLE+0.320
- MYC_TARGETS_V2+0.300
- INTERFERON_GAMMA_RESPONSE+0.290
- UV_RESPONSE_UP+0.270
- PANCREAS_BETA_CELLS+0.260
- HEDGEHOG_SIGNALING+0.230
Top 10 suppressed
- NOTCH_SIGNALING-0.500
- OXIDATIVE_PHOSPHORYLATION-0.300
- PROTEIN_SECRETION-0.300
- ADIPOGENESIS-0.250
- MYOGENESIS-0.250
- APICAL_JUNCTION-0.230
- ANGIOGENESIS-0.210
- UV_RESPONSE_DN-0.210
- CHOLESTEROL_HOMEOSTASIS-0.200
- ANDROGEN_RESPONSE-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-GM-A2DH-01A-11R-A180-07 | — | C | 0.813 |
| 2 | 83a1d91a-3e74-4106-96d1-eec558404c29 | — | — | 0.787 |
| 3 | TCGA-BH-A1FC-01A-11R-A13Q-07 | — | E | 0.783 |
| 4 | ERR2278873 | — | — | 0.781 |
| 5 | ERR2278859 | — | — | 0.756 |
| 6 | TCGA-BH-A209-01A-11R-A157-07 | — | D | 0.755 |
| 7 | MBCProject_1819_T1_RNA | — | C | 0.755 |
| 8 | SRR6013522 | — | cohortSQ1 | 0.752 |
| 9 | SRR8518297 | — | E | 0.749 |
| 10 | 20060324.TNBC | — | D | 0.746 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.620 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.550 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.380 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.270 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.060 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.060 | Idelalisib | — uncovered |